June 2021
Volume 62, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2021
THE MONTREAL EXPERIENCE: A RETROSPECTIVE STUDY PART II- ORTHO-K AND SOFT MULTIFOCAL LENS PERFORMANCES
Author Affiliations & Notes
  • Patrick Simard
    School of Optometry, Universite de Montreal, Montreal, Quebec, Canada
    Clinique d'Optométrie Bélanger, Montreal, Quebec, Canada
  • Langis Michaud
    School of Optometry, Universite de Montreal, Montreal, Quebec, Canada
  • Rémy Marcotte-Collard
    School of Optometry, Universite de Montreal, Montreal, Quebec, Canada
    Clinique d'Optométrie Bélanger, Montreal, Quebec, Canada
  • MHAMED OUZZANI
    Optometry, université d'oran, Oran, Tunisia
  • Footnotes
    Commercial Relationships   Patrick Simard, Bausch And Lomb (F), Cooper Vision (F), PCT/IB2018/059263 (P); Langis Michaud, Bausch and Lomb (F), Cooper Vision (F), PCT/IB2018/059263 (P); Rémy Marcotte-Collard, Bausch and Lomb (F), Cooper Vision (F), PCT/IB2018/059263 (P); MHAMED OUZZANI, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2021, Vol.62, 2334. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Patrick Simard, Langis Michaud, Rémy Marcotte-Collard, MHAMED OUZZANI; THE MONTREAL EXPERIENCE: A RETROSPECTIVE STUDY PART II- ORTHO-K AND SOFT MULTIFOCAL LENS PERFORMANCES. Invest. Ophthalmol. Vis. Sci. 2021;62(8):2334.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To evaluate the efficacy of different designs of orthokeratology (OK) soft multifocal lenses (SMCL) and low-dose atropine (LAD) to control myopia evolution. The primary outcome relates to axial length (AL) progression during 24 months.

Methods : This is a retrospective study based on data that are extracted from the file of each patient who: (1) consulted EOUM between Jan 2017 and Dec 2018 and (2) were kept under the same MCS (same design/concentration).
Clinical population is composed of 104 SMCL, 140 OK and 42 LDA participants. Elements analyzed include baseline age, gender, ethnicity, spherical equivalent refractive error (SEQ), photopic pupil size, flat and steep K readings. AL was also evaluated at baseline and after 6, 12 and 24 months. To assess whether intervention had a statistically significant effect, a complex statistical model was built. It was developed by first consider all collected parameters. Then, statistically insignificant predictor terms were removed using backward stepwise elimination. In the final model, 5 predictors were retained (month, SEQ, gender, age and age-month interaction).

Results : For OD only, considering SMCL, 4 designs are compared. AL variation at 12/24 months was: 0.14 +/- 0.18 (N=43) and 0.29 +/- 0.29 (N=22) for senofilcon A; 0.07 +/- 0.29 (N=16) and 0.33 +/- 0.66 (N=10) for comfilcon A, 0.18 +/- 0.15 (N=18) and 0.33 +/- 0.25 (N=9) for Omafilcon Toric, 0.13 +/- 0.1 (N=8) and 0.2 +/- 0.06 (N=5) for etafilcon A. About OK lenses, AL results are: 0.18 +/- 0.19 (N=40) and 0.35 +/- 0.27 (N=36) for HDS 5 curves, 0.05 +/- 0.19 (N=44) and 0.17 +/- 0.29 (N=19) for custom 7 curves design; 0.13 +/- 0.17 (N=16) and 0.23 +/- 0.19 (N=11) for custom double-reservoir design, 0.03 +/- 0.18 (N=13) and 0.21 +/- 0.33 (N=15) for a 4 zones VST design. LDA results are 0.21 +/- 0.16 (N=34) and 0.37 +/- 0.25 (N=19). There was no statistical difference between SMCL or OK lenses, within the same category. However, OK leaded to significant better control after 1 year, which was no longer true after 24 months (see part 1)

Conclusions : When correctly selected at baseline, there is no long term difference between contact lens modalities used to control myopia evolution. OK lenses seem to give better results at the beginning but SMCL becomes as efficient with time. Atropine seems to lead to increased evolution at any time point.

This is a 2021 ARVO Annual Meeting abstract.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×